Biopharmaceutical company Faron Pharmaceuticals Ltd (AIM: FARN) (First North: FARON) on Monday reported new Phase I/II BEXMAB trial data showing enhanced efficacy for its lead asset, bexmarilimab, in treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients. The results were presented by Dr Mika Kontro of Helsinki University Hospital at the European Society for Medical Oncology (ESMO) Congress 2025.

In combination with azacitidine, bexmarilimab achieved an 85% objective response rate (ORR) and a 45% complete remission rate in 20 evaluable treatment-naïve HR-MDS patients. More than half of patients (55%) achieved full clearance of bone marrow blasts, with deeper engagement of the Clever-1 target correlating strongly with improved outcomes. Patients with low baseline blast counts (